Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (20608)	5/12/1998 4:42:00 PM
From: bob zagorin	Read Replies (1) \| Respond to of 32384

i know there are some michael murphy haters on this thread but that is essentially the argument he has been making for several years. to wit: 1. intracellular biotech research is one of if not the next big wave in technology investing 2. the entire market cap of the top 10-12 research companies in this field (I believe his choices were LGND, ISIP, VICL, SUGN, RZYM, ARRS & SQNA[now merged to AXPH], GNTA, AMLN and several others) was less than NSCP at that time. it made sense to me then and it still makes sense